NYXH Nyxoah

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Nyxoah to Release Second Quarter 2023 Financial Results

on August 8, 2023

Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter of 2023 on Tuesday, August 8, 2023, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.

A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: . For those not planning to ask a question of management, the Company recommends listening via the webcast.

If you plan to ask a question, please use the following link: . After registering, an email will be sent, including dial-in details and a unique conference call access code required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call.

The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and U.S. commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

David DeMartino, Chief Strategy Officer



Attachment



EN
27/07/2023

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 27, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares. Share capital: EUR 6,431,121.38 Total number of securities carrying voting rights: 37,435,640 (all ordinary shares) Total number of voting rights (= denominator): 37,4...

June 27, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Informations sur le nombre total de droits de vote et d'actions

Informations sur le nombre total de droits de vote et d'actions INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 27 juin 2025, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci-dessous suite à l'émission de nouvelles actions. Capital: EUR 6.431.121,38 Nombre total de titres avec droits de vote: 37.435.640 (tous des actions ordinaires) Nombre total de droits de v...

June 27, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Invitation to attend the extraordinary shareholders’ meeting of the Co...

Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 REGULATED INFORMATIONJune 13, 2025, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 2, 2025 The board of directors of the Company is pleased to invite its securities holders to attend the extraordinary shareholders' meeting of the Company, to be held on Wednesday, July 2, 2025 at 2:00 p.m. CET at...

June 13, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Invitation à assister à l'assemblée générale extraordinaire des action...

Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 2 juillet 2025 INFORMATIONS RÉGLEMENTÉESle 13 juin 2025, 7:00h CET / 1:00h ET NYXOAH SA(Euronext Brussels/Nasdaq: NYXH)Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgique(ci-après la « Société ») Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 2 juillet 2025 Le conseil d'administration de la Société a le plaisir d'inviter ses détenteurs de titres à assister à l’assemblée générale extraordinaire des actionnaires de la...

June 13, 2025 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relating to transparency notifications

Publication relating to transparency notifications                  REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 30, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Vestal Point Capital On May 27, 2025, Nyxoah received a transparency notification from Vestal Point Capital following an acquisition or disposal of voting securities...

May 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch